The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
暂无分享,去创建一个
[1] R. Gniadecki,et al. Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage , 2015, Leukemia & lymphoma.
[2] Charlotte M. Miller,et al. Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells , 2014, Investigational New Drugs.
[3] V. Arlt,et al. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. , 2014, Toxicology.
[4] E. Frei,et al. Ellipticines as DNA-targeted chemotherapeutics. , 2014, Current medicinal chemistry.
[5] V. Adam,et al. Expression Levels of Enzymes Metabolizing an Anticancer Drug Ellipticine Determined by Electromigration Assays Influence its Cytotoxicity to Cancer Cells - A Comparative Study , 2014, International Journal of Electrochemical Science.
[6] V. Arlt,et al. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice. , 2013, Neuro endocrinology letters.
[7] D. Dasgupta,et al. Ellipticine binds to a human telomere sequence: an additional mode of action as a putative anticancer agent? , 2013, Biochemistry.
[8] C. Wolf,et al. Evidence That Cytochrome b5 and Cytochrome b5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P450 System , 2013, Molecular Pharmacology.
[9] W. J. Andrews,et al. Old Drug, New Target , 2013, The Journal of Biological Chemistry.
[10] R. Kizek,et al. The Anticancer Drug Ellipticine Induces Cytochromes P450 1A1, 1A2 and 3A, Cytochrome b5 and NADPH:Cytochrome P450 Oxidoreductase in Rat Liver, Kidney and Lung , 2013 .
[11] R. Kizek,et al. Electrochemical Determination of Enzymes Metabolizing Ellipticine in Thyroid Cancer Cells - a Tool to Explain the Mechanism of Ellipticine Toxicity to these Cells , 2013, International Journal of Electrochemical Science.
[12] C. Wolf,et al. Evidence That Cytochrome b 5 and Cytochrome b 5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P 450 System s , 2013 .
[13] Z. Dvořák,et al. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. , 2012, Toxicology.
[14] Charlotte M. Miller,et al. Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles , 2012 .
[15] V. Arlt,et al. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. , 2012, Toxicology letters.
[16] V. Adam,et al. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. , 2012, Current medicinal chemistry.
[17] F. Guengerich,et al. Contributions of human enzymes in carcinogen metabolism. , 2012, Chemical research in toxicology.
[18] R. Kizek,et al. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. , 2012, Chemical research in toxicology.
[19] V. Adam,et al. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. , 2012, Pharmacology & therapeutics.
[20] Jieun Park,et al. Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. , 2011, Toxicology.
[21] J. Hudeček,et al. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. , 2011, Biochemical pharmacology.
[22] V. Arlt,et al. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[23] R. Kizek,et al. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. , 2011, Neuro endocrinology letters.
[24] E. Frei,et al. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. , 2011, Biochimica et biophysica acta.
[25] Yunfeng Zhao,et al. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells , 2011, Apoptosis.
[26] Václav Martínek,et al. Glycosylation protects proteins against free radicals generated from toxic xenobiotics. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[27] K. Takeda,et al. α5β1 integrin antagonists reduce chemotherapy‐induced premature senescence and facilitate apoptosis in human glioblastoma cells , 2010, International journal of cancer.
[28] Barbora Mrázová,et al. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. , 2010, Neuro endocrinology letters.
[29] O. Hankinson,et al. Functional Characterization of Human Cytochrome P450 2S1 Using a Synthetic Gene-Expressed Protein in Escherichia coli , 2009, Molecular Pharmacology.
[30] O. Hankinson,et al. Fatty Acid Hydroperoxides Support Cytochrome P450 2S1-Mediated Bioactivation of Benzo[a]pyrene-7,8-dihydrodiol , 2009, Molecular Pharmacology.
[31] Václav Martínek,et al. Preparation of a biologically active apo-cytochrome b5 via heterologous expression in Escherichia coli. , 2009, Protein expression and purification.
[32] R. Kizek,et al. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. , 2009, Biochemical pharmacology.
[33] D. Waxman,et al. Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer , 2009, Cancer Gene Therapy.
[34] K. Fang,et al. Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells. , 2009, Lung cancer.
[35] E. Frei,et al. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. , 2009, Neuro endocrinology letters.
[36] R. Finn,et al. Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5*S⃞ , 2008, Journal of Biological Chemistry.
[37] J. Hudeček,et al. Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. , 2008, Neuro endocrinology letters.
[38] X. Qi,et al. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. , 2008, Kidney international.
[39] V. Arlt,et al. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. , 2008, Toxicology and applied pharmacology.
[40] V. Arlt,et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo : experiments with Hepatic Cytochrome P450 Reductase Null mice , 2008 .
[41] J. Dennis,et al. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization , 2008, Apoptosis.
[42] D. Waxman,et al. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment , 2007, Molecular Cancer Therapeutics.
[43] L. Waskell,et al. Cytochrome b5 Increases the Rate of Product Formation by Cytochrome P450 2B4 and Competes with Cytochrome P450 Reductase for a Binding Site on Cytochrome P450 2B4* , 2007, Journal of Biological Chemistry.
[44] R. Vaclavikova,et al. The Anticancer Drug Ellipticine Is a Potent Inducer of Rat Cytochromes P450 1A1 and 1A2, Thereby Modulating Its Own Metabolism , 2007, Drug Metabolism and Disposition.
[45] E. Frei,et al. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. , 2007, Cancer letters.
[46] E. Frei,et al. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. , 2007, Toxicology.
[47] E. Frei,et al. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.
[48] E. Frei,et al. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. , 2006, Neuro endocrinology letters.
[49] J. Hudeček,et al. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. , 2006, General physiology and biophysics.
[50] Eva Frei,et al. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. , 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[51] Chun-ching Lin,et al. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. , 2006, Life sciences.
[52] V. Arlt,et al. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. , 2006, Cancer letters.
[53] J. Hudeček,et al. The Effect of pH on Peroxidase-Mediated Oxidation of and DNA Adduct Formation by Ellipticine , 2006 .
[54] L. Waskell,et al. Role of cytochrome b5 in catalysis by cytochrome P450 2B4. , 2005, Biochemical and biophysical research communications.
[55] Graeme I Murray,et al. Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers , 2005, Clinical Cancer Research.
[56] Oliver Hankinson,et al. CYP2S1: a short review. , 2005, Toxicology and applied pharmacology.
[57] Chun-ching Lin,et al. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. , 2005, Cancer letters.
[58] C. Wolf,et al. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. , 2005, Cancer research.
[59] Chun-ching Lin,et al. The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction , 2005, Anti-cancer drugs.
[60] B. Sopko,et al. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.
[61] Marie Stiborová,et al. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid‐DNA adducts found in patients with urothelial cancer , 2005, International journal of cancer.
[62] J. Hudeček,et al. The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.
[63] M. Poirier. Chemical-induced DNA damage and human cancer risk , 2004, Nature Reviews Cancer.
[64] N. Garbett,et al. Extending nature's leads: the anticancer agent ellipticine. , 2004, Current medicinal chemistry. Anti-cancer agents.
[65] E. Frei,et al. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.
[66] Jiandong Chen,et al. Rescue of mutant p53 transcription function by ellipticine , 2003, Oncogene.
[67] David Bouwman,et al. Cytochrome p450 and glutathione transferase expression in human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] C. Wolf,et al. Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.
[69] J. Schenkman,et al. The many roles of cytochrome b5. , 2003, Pharmacology & therapeutics.
[70] E. Frei,et al. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. , 2003, Chemical research in toxicology.
[71] E. Frei,et al. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.
[72] H. Yamazaki,et al. Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. , 2001, The Journal of biological chemistry.
[73] R. Godschalk,et al. Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons. , 2000, Carcinogenesis.
[74] S. McKeown,et al. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. , 1999, Anti-cancer drug design.
[75] E. Sugikawa,et al. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. , 1999, Anticancer research.
[76] M. Sefkow,et al. Epothilone A-D and their thiazole-modified analogs as novel anticancer agents , 1999 .
[77] P. Wormell,et al. Spectroscopic studies of 9-hydroxyellipticine binding to DNA. , 1998, Biopolymers.
[78] J N Weinstein,et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.
[79] H. Yamazaki,et al. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. , 1997, Archives of biochemistry and biophysics.
[80] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[81] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[82] E. Sugikawa,et al. Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism , 1995, Japanese journal of cancer research : Gann.
[83] G. Murray,et al. Cytochrome P450 expression in tumours. , 1995, The Journal of pathology.
[84] N. Osheroff,et al. Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA. , 1995, The Journal of Biological Chemistry.
[85] F. Beland,et al. DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene. , 1995, Cancer Research.
[86] S. Nesnow,et al. Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. , 1995, Cancer research.
[87] M. Singh,et al. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. , 1994, Biochemistry.
[88] M. Waterman. Heterologous expression of cytochrome P-450 in Escherichia coli. , 1993, Biochemical Society transactions.
[89] M. Fritsche,et al. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.
[90] C. Paoletti,et al. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. , 1992, Molecular pharmacology.
[91] M. Hsu,et al. Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. , 1992, Nucleic acids research.
[92] T. Eling,et al. Xenobiotic metabolism by prostaglandin H synthase. , 1992, Pharmacology & therapeutics.
[93] C. Paoletti,et al. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. , 1991, Nucleic acids research.
[94] J. Bergman,et al. 1H-NMR studies of the interaction between a self-complementary deoxyoligonucleotide duplex and indolo[2,3-b]quinoxaline derivatives active against herpes virus. , 1991, European journal of biochemistry.
[95] J. Belehradek,et al. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. , 1991, The Journal of biological chemistry.
[96] T. Eling,et al. Prostaglandin H synthase and xenobiotic oxidation. , 1990, Annual review of pharmacology and toxicology.
[97] C. Auclair. Multimodal action of antitumor agents on DNA: the ellipticine series. , 1987, Archives of biochemistry and biophysics.
[98] K Randerath,et al. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. , 1984, Carcinogenesis.
[99] D. Phillips,et al. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. , 1984, Carcinogenesis.
[100] D. Silveira,et al. Comparative physiological disposition of ellipticine in several animal species after intravenous administration. , 1978, Drug metabolism and disposition: the biological fate of chemicals.
[101] V. Reinhold,et al. Characterization of the metabolites of ellipticine in rat bile. , 1978, Drug metabolism and disposition: the biological fate of chemicals.
[102] K W Kohn,et al. Intercalative binding of ellipticine to DNA. , 1975, Cancer research.